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”If you want to build a ship, don’t drum up people together to
collect wood and don’t assign them tasks and work, but rather
teach them to long for the endless immensity of the sea . . . ”
”How could drops of water know themselves to be a river? Yet
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Summary
Hyperglycemia in intensive care patients is associated with increased mor-
tality and prolonged illness. Tight blood glucose control reduces mortality
and morbidity in some groups of critically ill patients, but increases the risk
of hypoglycemia. Fear of hypoglycemia, and the required time and effort
have yet prohibited tight blood glucose control to become a standard of care
in intensive care units.
This thesis hypothesizes, that a decision support system can be built that
improves blood glucose control in critically ill patients without increasing
the risk of hypoglycemia. The thesis summarizes the design, development
and clinical pilot testing of the model-based computerized decision support
system ’Glucosafe’. This system recommends not only insulin dosing, but
also nutrition for optimized blood glucose control. The system is based on a
physiological multi-compartment model of insulin and glucose. Insulin resis-
tance is modeled as a time-varying, patient-specific parameter, that reduces
the maximal achievable insulin effect. The model also accounts for the sat-
uration of insulin effect at high insulin concentrations, thus preventing the
recommendation of insulin doses that lead to hypoglycemia. Recommen-
dations are based on a set of penalty functions, that minimize the risks of
hypo- or hyperglycemia, undernourishment or overfeeding. Recommenda-
tions include the route of feeding, giving early enteral feeding priority over
parenteral nutrition. Finally, the system includes a feature to change the
advice mode, in order for the system to recommend exclusively the dosing
of insulin.
A retrospective evaluation of Glucosafe’s accuracy to predict blood glu-
cose concentrations showed a median error of less than 25% by the model
for predicted values up to 270 minutes ahead in time. The prospective pi-
lot testing of Glucosafe was carried out at the neuro- and trauma intensive
care unit of Aalborg hospital in Denmark. Ten hyperglycemic patients were
studied in an ’off-on-off’ study design. Results showed that Glucosafe im-
proved the blood glucose control significantly. Hypoglycemia did not occur
during the trial. These results are preliminary and need to be confirmed by
a large randomized clinical trial to reach a definite conclusion. The thesis
concludes with outlining the workflow to include Glucosafe as a standard
care tool for blood glucose control in intensive care units.
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Chapter 1
Introduction
1.1 Hyperglycemia in critical care
Normal fasting blood glucose concentration ranges from approximately 4.0−
6.0 mmol/L in healthy adults [8]. Hyperglycemia is the commonly used
term for abnormally high blood glucose concentrations; however, there are
discrepancies with respect to the cut-off value by which the start of hy-
perglycemia is defined [9]. In patients with diabetes mellitus, high blood
glucose is a chronic condition; measured values are used to diagnose the
disease and to monitor the treatment course. However, hyperglycemia has
also been observed in critically ill patients with no prior history of diabetes.
The terms ’stress hyperglycemia’ and ’transient hyperglycemia’ have been
proposed to describe this state [9; 10]. The content of this thesis focuses on
hyperglycemia in critical illness, unless otherwise stated.
Severe traumatic injury is characterized by an initial hypometabolic re-
sponse, followed by a longer-lasting, hypermetabolic phase [11]. These states
are sometimes also referred to as ’ebb’ and ’flow’ phase of critical illness [11].
The ebb phase ceases after about 12 to 14 hours, while the duration of the
flow phase depends on the severity of injury or infection; it typically peaks
at around 3 to 5 days post-injury and subsides after 7 to 10 days [12]. Hy-
perglycemia is common during both phases, although for different causes.
During the ebb phase, hyperglycemia is related to an increase in plasma
epinephrine concentration which rises progressively with severity of injury
shortly after the assault and causes an increase of hepatic glycogenolysis [13].
Another source for early hyperglycemia in this phase is the stress-induced
activation of a feedback loop between two organ systems, the hypothalamic-
pituitary-adrenal axis and the sympathetic nervous system, that leads to
increased levels of cortisol [14]. Cortisol is a counter-regulatory hormone
that induces the biosynthesis of gluconeogenic enzymes and inhibits glucose
uptake and metabolism in peripheral tissues. In the flow phase, hyper-
glycemia mainly results from a combination of glucagon-stimulated hepatic
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gluconeogenesis [15] and peripheral and central insulin resistance [12]. El-
evated glucagon levels in patients with hypermetabolic stress may reflect
direct effects of tumor necrosis factor [16], a pro-inflammatory cytokine.
Tumor necrosis factor and other cytokines, for example interleukin-1 and
interleukin-6, also seem to be involved in the inhibition of insulin release
[17] and in the impairment of insulin action on peripheral glucose disposal
[18]. They are thus seen as important mediators of stress-induced insulin re-
sistance. Other factors contributing to hyperglycemia during stress include
total parenteral nutrition [19; 20], a history of diabetes mellitus, cirrhosis,
pancreatitis, administration of certain drugs (for example corticosteroids),
hypokalaemia and chromium deficiency [12].
The prevalence of hyperglycemia varies for different groups of critically
ill patients, differently defined cut-off points and different diagnostic time
points. In a study of children and adolescents attending paediatric emer-
gency care, hyperglycemia occurred in 3.8% of screened patients and was
defined as glucose concentration ≥ 8.3mmol/L at admission time [21]. An-
other retrospective study reported 4.9% prevalence of stress hyperglycemia
in paediatric patients by the same definition criteria; however, as the study
investigators noted, the prevalence was significantly higher in children af-
fected by febrile seizures (12.9%) or traumatic injuries (11.7%), compared
to other diagnoses [22]. Van den Berghe et al. [23] reported that 12% of
critically ill adult patients had blood glucose levels exceeding 11.1 mmol/L
shortly after surgery. In a study by Latham et al. [24], 21% of nondiabetic
cardiothoracic surgery patients had developed postoperative blood glucose
levels exceeding 11.1 mmol/L within 48 hours after surgery. The same au-
thors showed that hyperglycemia occurred more often in patients with sur-
gical site infections than in patients without surgical site infections; this
observation was made for patients with and patients without a known his-
tory of diabetes [24]. Wide variations in hyperglycemia prevalence have been
seen in nondiabetic patients after acute myocardial infarction, stress hyper-
glycemia having been reported in 3% to 71% of patients [25]. In hospitalized,
severe sepsis patients without pre-diagnosed diabetes, 17.7% were found to
have admission or fasting blood glucose levels exceeding 7 mmol/L [26]. Fi-
nally, in a study of trauma ICU1 patients and different hyperglycemic cut-off
points, blood glucose values exceeded 6.1 mmol/L in 93%, 8.3 mmol/L in
60% and 11.1 mmol/L in 17% of the patients, respectively [27].
A meta-analysis of 15 observational studies showed that among critically
ill nondiabetic patients with myocardial infarction, those with glucose lev-
els in the range of 6.1 - 8.0 mmol/L had an almost four-fold higher risk of
death than patients with lower glucose values [25]. Similarly, acute hyper-
glycemia following stroke has been found to be associated with a two to
threefold increased mortality and significant impairment in functional re-
1Intensive Care Unit
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covery [28; 29]. Leonidou et al. [26] reported a mortality rate of 43% in
hospitalized hyperglycemic patients with severe sepsis, compared to 16% in
normoglycaemic patients with severe sepsis. The relationship between the
extent of hyperglycemia and mortality has been shown to be independent of
injury characteristics and patient demographics in various groups of inten-
sive care and hospital care patients [27; 30; 31]. Hyperglycaemia in critical
illness has also been associated with increased severe infection [32], sepsis
and septic shock [10] and multiple-organ failure [33].
In a multi-centre retrospective observational study, Egi et al. [34] demon-
strated a significant positive association between reduced patient standard
deviation (’variability’) of blood glucose and decreased mortality risk for
nondiabetic patients with different disease backgrounds. Surprisingly, the
authors found that variability of glucose concentration was an independent
and stronger predictor of mortality in the ICU than mean glucose concen-
tration [34]. There is no clear understanding of the underlying mechanism
to this finding. However, a study of type 2 diabetes patients demonstrated
that fluctuations in glucose concentration may trigger adverse biologic events
beyond those of chronic sustained hyperglycemia, and specifically and inde-
pendently trigger oxidative stress [35]. Based on their findings, Egi et al.
[34] hypothesized that glucose control should be aimed to reduce both abso-
lute mean values and blood glucose variability in order to achieve survival
benefits.
1.2 Glycemic control in the ICU
In a landmark randomized controlled trial of 1548 surgical intensive care
patients, the outcomes of intensive insulin therapy with a glucose target of
4.4 to 6.1 mmol/L were demonstrated by van den Berghe et al. [23]. The
mean morning blood glucose level (± standard deviation) was 5.7 mmol/L
(±1.1 mmol/L) in the group receiving intensive insulin treatment, and 8.5
mmol/L (±1.8 mmol/L) in the conventionally treated control group (con-
trols receiving insulin treatment at blood glucose levels of 12 mmol/L or
higher). Intensive insulin therapy reduced the risk of organ failure and ICU
mortality by up to 45% [23]. The greatest survival benefits could be seen in
patients who stayed five days or longer in the ICU. The in-hospital mortal-
ity was reduced by 34%, bloodstream infections by 46%, acute renal failure
requiring dialysis or hemofiltration by 41%, the median number of red-cell
transfusions by 50%, and critical-illness polyneuropathy by 44%. Patients
in the intensive insulin treatment group were also less likely to require pro-
longed mechanical ventilation, and they were earlier discharged than con-
trols. Severe hypoglycemia (blood glucose ≤ 2.2 mmol/L) occurred in 5.1%
of patients in the intervention group compared to 0.8% in controls.
Some of the results by van den Berghe et al. [23] could be replicated in
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clinical trials which used historic patient records as controls. One of the first
studies was done by Krinsley [36] with a heterogeneous group of patients
from a medical-surgical ICU. Intensive glucose management (the glucose
target was < 7.75 mmol/L) reduced overall in-hospital mortality by 29%
compared to a group of historic controls. The survival benefit was greatest
for neurologic patients and for patients with septic shock, where mortal-
ity fell from 21.0% to 8.5% (P=.007), and from 60.4% to 33.3% (P=.02),
respectively. Other significant improvements included reductions in the de-
velopment of new renal insufficiency by 75%, in the number of patients
requiring red-cell transfusion by 19%, and in the length of stay in inten-
sive care by 11%. The median (interquartile range) blood glucose level for
the historic control group was 7.3 mmol/L (5.9 − 9.5 mmol/L). This value
decreased to 6.6 mmol/L (5.5 − 8.2 mmol/L) for the intervention group. Se-
vere hypoglycemia (blood glucose ≤ 2.2 mmol/L) occurred in 0.34% among
intensively treated patients with no significant change compared to controls.
In another single-centre study with historic controls, Chase et al. [37]
reported a relative decrease of in-hospital mortality by 35%, from 31.9% to
20.6% (P=.02), for patients who had stayed in intensive care for at least five
days. In their general ICU, strict blood glucose control was adopted as a
clinical practice change. The frequency of severe hypoglycemia was 0.1% of
all measurements with their SPRINT2 protocol, which was a 50% reduction
compared to the historic control group [37].
In contrast to studies with historic controls, randomized controlled stud-
ies were unable to replicate the mortality reduction and other results seen
by van den Berghe and her team [23]. One well-reputated case is the VISEP
study. This study was designed as multi-centre, two-by-two factorial trial,
where patients with severe sepsis were assigned to one of two groups receiv-
ing intensive insulin therapy or conventional insulin treatment [38]. The
trial was stopped early after a massive encounter of severe hypoglycemia
(17% vs. 4.1%, P=.01) and an increase of the rate of serious adverse events
(10.9% vs. 5.2%, P=.01) in the two intensive insulin groups, while there
was no significant difference in the rate of death or the mean score for organ
failure.
The results of the NICE-SUGAR (Normoglycaemia in Intensive Care
Evaluation Survival Using Glucose Algorithm Regulation) trial [39] were
even more contrary to the van den Berghe study. The primary outcome
variable, 90-day mortality, was actually increased in patients randomly as-
signed to intensive insulin therapy, as compared with an intermediate target
range for blood glucose. These findings, reflecting data collected in a set of
more than 6,000 patients, contradicted the external validity of tight glucose
control [40].
It has been hypothesized that the survival benefits of intensive insulin
2Specialized Relative Insulin Nutrition Tables
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therapy seen in the first van den Berghe study [23] may have been due
to protective effects of insulin on the endothelium, mediating prevention
of organ failure and death [33; 41]. A subsequent randomized controlled
trial by van den Berghe et al. in medical ICU patients found similar organ
protective effects; however, morbidity but not mortality was reduced in the
intention-to-treat analysis [42]. Moreover, 18.7% of the intensively treated
patients experienced at least one episode of severe hypoglycemia.
In a meta-analysis of 26 randomized controlled clinical trials by Gries-
dale et al., the authors concluded that intensive insulin therapy does not
provide significant survival benefits, except in surgical patients [43]. The
meta-analysis was based on results from intention-to-treat analyses and re-
vealed a significant heterogeneity with respect to mortality results among the
included trials. 16 of the studies used a glycemic target of ≤ 6.1 mmol/L for
their intervention groups; 9 trials used a glycemic target of ≤ 8.3 mmol/L.
The results did not reveal to which extent glycemic targets had been reached,
or whether lack compliance correlated with their mortality findings. Based
on a sub-analysis of 14 trials, the authors also found a six-fold higher risk
of severe hypoglycaemia (blood glucose ≤ 2.2 mmol/L) among intensively
treated patients compared to controls [43]. The correlation between in-
creased risk of hypoglycemia and increased risk of death was however not
tested.
Preiser et al. [44] showed in a multi-centre trial with medical and surgical
intensive care patients that the occurrence of hypoglycemia induced a two-
fold increased risk of death independent of the blood glucose target range.
They also found that more severely ill patients were at a higher hypoglycemic
risk, thus showing that the risk of hypoglycemia and the risk of death may
be linked by severity of illness [44].
Another explanation for a higher mortality risk with severe hypoglycemia
could be hypoglycaemia-induced oxidative stress and neuronal cell death
during glucose reperfusion [45]. Irrespective of the cause is the minimiza-
tion of the hypoglycemia risk of the greatest importance. However, current
tight glycemic control protocols are primarily based on clinical experience.
They require significant costs and efforts for their implementation and main-
tenance, however, results are highly variable with respect to achievement of
targeted blood glucose levels and hypoglycemia [43; 46; 47; 48]. Therefore,
they are not optimal for blood glucose control of critical care patients.
The degree of compliance to a protocol influences the outcome of tight
glycemic control studies. The association between hyperglycemia and non-
adherence to a tight glucose control protocol (4.4 − 6.1 mmol/L) was retro-
spectively investigated in an analysis of 1106 trauma and surgical intensive
care patient records [49]. The investigators assessed, whether blood glucose
measurements had been on schedule. It was found, that the timing had
a significant impact on blood glucose control, and that late measurements
were more often associated with severe hyperglycemia (> 8.3 mmol/L) or
15
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hypoglycemia (< 3.3 mmol/L). Other studies found that protocol violations
seriously compromise the effectiveness of a tight glycemic control strategy
[50], and may even lead to its abandonment [44].
In addition to protocol compliance, the accuracy of blood glucose mea-
surement devices is important for the success of tight glycemic control in
intensive care. Arterial blood analysis has a significantly higher agreement
with central laboratory measurements than capillary blood analysis [51; 52].
During hypoglycemia, agreement with central laboratory measurements was
only 26.3% using capillary blood analysis in an observational study of point-
of-care glucose measurement devices, and 55.6% and 64.9% for glucose me-
ter and blood gas/chemistry analysis of arterial blood [51]. Glucose meters
tend to overestimate whole blood glucose levels, whereas methods of arterial
blood analysis tend to underestimate glucose values [51; 52; 53]. At high
risk of hypoglycemia, blood gas/chemistry analysis of arterial blood should
therefore be given priority over glucose meters, if laboratory measurements
are not feasible.
Carbohydrate-rich nutrition and total parenteral nutrition exacerbate
glucose levels [20; 54]. In contrast, low and moderate caloric intakes, prefer-
ably via the enteral route, have been associated with significantly lower inci-
dences of hyperglycemia and improved patient outcomes [55; 56; 57]. How-
ever, prolonged hypocaloric enteral feeding should be avoided and parenteral
nutrition should be added if caloric-protein targets cannot be achieved after
several days [58]. Current research favours early initiation of enteral feed-
ing if the gastrointestinal tract is functioning. According to a systematic
review, early enteral feeding reduces the risk of hyperglycemia and reduces
the need for insulin therapy [59]. Hence, nutrition provides an alternative
control measure in addition to insulin.
1.3 Model-based glucose control
Conventional glycemic control methods respond to a measured blood glu-
cose value with the prescription of a predefined insulin dose. Protocol im-
plementations of such methods can be roughly divided into ’sliding scale’ or
’dynamic’ insulin titration protocols [46]. Sliding scale protocols prescribe
standardized bolus sizes or insulin infusion rates for defined blood glucose
ranges. Dynamic scale protocols combine a glucose target and for example
the last two blood glucose values to determine the insulin infusion rate or
bolus size [46]. Variants of these two basic types can be distinguished with
regard to their complexity, their consideration of patient characteristics, the
targeted blood glucose range, the degree of their automatization, the unam-
biguousness of their directives, and the allowed time to next measurement.
Model-based methods predict the outcome of a certain intervention, such
as of a certain infusion size, and base their recommendation on the predicted
16
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outcome that best matches a predefined target. Predictions are based on
a model, which is representative of the glucose-insulin metabolism of the
patient. The type of input to a model can vary, however, generally required
are measured blood glucose concentrations and data regarding insulin ther-
apy. Typically will the input of new data trigger the reassessment of one
or more patient parameters, which are thereafter used by the model in the
simulation of the outcomes of possible interventions.
Model-based methods are often implemented as computer programs, al-
though adaptations to paper protocols have been successully tried, such as
with the SPRINT protocol [37]. Computer implementations of model-based
control algorithms can graphically display the history or the future trend
of a patient’s clinical treatment, they may come with alarm functions, they
may be capable of being integrated in electronic patient journals, or they can
be designed to communicate with clinical information systems, for example
in order to retrieve blood glucose values from electronic databases.
Models of glucose metabolism and insulin effect can be traced as far back
as to the early 1970s [60; 61]. Computerized model-based control systems
were introduced for educational purposes and for the improvement of insulin
therapy in diabetes [62; 63; 64]. However, diabetes care models have been
subsequently modified and tested in a critical care environment, since it can
be argued, that the principles of pharmacokinetics and -dynamics work not
differently in diabetes and in stress hyperglycemia [65; 66].
Of the clinically tested, computerized decision-support systems [67], only
very few are model-based, while the majority are electronic versions of a dy-
namic or a sliding scale protocol. These are mostly ’carbohydrate-blind’, i.e.
they do not account for the carbohydrate intakes of patients. Nutritional
advice is also not generally given, and is limited to include measures for
counteracting hypoglycemia, for example by a glucose bolus [67]. In con-
trast, the model-based SPRINT protocol [37] makes use of a paper wheel to
decide on insulin bolus sizes and nutrition intake. SPRINT was successfully
implemented as a clinical practice change in a general medical ICU; how-
ever, a strict scheduling of blood glucose measurements (every 1-2 hours) is
required, and none of the advantages of a computerized solution are offered.
1.4 Hypothesis
It is hypothesized, that model-based computer decision support can improve
the blood glucose control of critically ill patients without increasing the risk
of hypoglycemia.
17
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1.5 Research Objectives
• Define the structure of a model that captures the relevant physiological
processes involved, that can be identified from routine clinical data
• Find an appropriate method for making clinically relevant recommen-
dations of insulin dosing and nutrition for treating hyper- or hypo-
glycemia
• Develop and test a computer decision support system based on the
model and recommendation method in a clinical trial
• Find the means that enable this system to be incorporated into the
routine management of ICU patients
18
Chapter 2
Model Structure
In this chapter the structure of the model will be described. The content is
based on publications I and II.
The proposed model for the glycemic control system ’Glucosafe’ is shown
in Figure 2.1. It is a physiological compartment model of insulin kinetics
and glucose metabolism [1].
Figure 2.1: Glucosafe’s compartment model structure (modified from [1])
The two compartments on the left of Figure 2.1 describe the insulin
pharmacokinetics. The ’plasma’ compartment I comprises plasma and hep-
atic space and the ’peripheral’ compartment Q represents the distribution
space of insulin in the extracellular interstitial fluid. Intravenous infusions
and bolus injections are the exogenous input P , and pancreatic insulin ap-
pears (after first passing through the liver) as continuous input U in the
plasma compartment. Insulin removal is modelled as the sum of hepatic
and renal insulin clearance, nL and nK , and the net transport rate nI from
plasma to the peripheral compartment. In the peripheral compartment,
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insulin molecules bind to receptors at the cell surfaces. The bound-insulin-
receptor complex is endocytised and subsequently degraded within the cell.
nC denotes the intracellular degradation rate.
Volumes VP and VQ and fractional turnover rates of the compartments
are calculated from demographic data (sex, age, height, weight, diabetic
state) using standard equations for clearance of C-Peptide [68]. From the
volumes and fractional turnover rates the net transport rate nI is calcu-
lated and subsequently adjusted for the molecular mass difference between
C-Peptide and insulin molecules. The insulin clearance rates, nL and nK ,
are calculated from steady-state assumptions in the model equations and
experimental data from type 1 diabetic patients [1]. The endogenously pro-
duced insulin U is assumed to be a constant rate at a value of 42 mU/min
for patients without type 1 diabetes. This value has been found to give opti-
mal simulation results in a retrospective trial of 10 critical care patients [1].
Since this value is higher than reported ranges in healthy normal and obese
subjects [69], in this model it is interpreted as a marker for an increased pro-
duction of endogenous insulin in response to stress-induced hyperglycemia.
Figure 2.2: Endogenous glucose balance as function of peripheral insulin
(modified from [2])
The box in the middle of Figure 2.1 is a description of the pharmaco-
dynamic effect of insulin, i.e. the concentration-dependent effect on insulin-
mediated glucose uptake. This effect is described as a non-linear trans-
formation in Figure 2.2, where the maximal endogenous glucose turnover
(’endogenous balance’) is a function of the peripheral insulin concentration.
The function values are normalized; a value of 1 thus represents the maxi-
mum insulin effect that is achievable on the endogenous balance. Saturation
effects on glucose turnover at high insulin concentrations in the interstitium
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have been shown in a number of studies [70; 71; 72; 73; 74].
Figure 2.2 marks the half-effect concentration, which is a concentration
of about 24 mU/L in the interstitium, corresponding to about 40 mU/L
in plasma, if it is assumed that the extracellular insulin concentration seen
by the tissues is about 60% of the plasma concentrations in steady state
[75]. From experiments performed by different groups in type 1 diabetes
patients (see [74] for references) it was found that the average plasma insulin
concentration Ī in response to the insulin infusion rate INFR could be
calculated as:
Ī = INFR ∗ C (2.1)
where C = 98.1 (kg · min)/L. Thus, an infusion rate of 0.4 mU/(kg · min),
i.e. a rate of 1.7 U/h in a 70 kg subject, is sufficient to reach half effect on
insulin-mediated glucose turnover. From Figure 2.2 it can be seen that for
a peripheral insulin concentration of 80 mU/L, the endogenous balance is
about 90% and only marginal increases are achievable for higher concentra-
tions. In a 70 kg subject, 90% endogenous balance is reached by continuously
infusing 5.7 U/h, or 7.3 U/h in a 90 kg subject. This means that in pro-
tocols which permit much higher infusion rates, insulin therapy as the only
measure to control blood glucose ceases to be an effective tool [2]. Quite the
contrary, hypoglycemia can be aggravated by the relatively slow diffusion
of insulin across the vascular bed, from the interstitial fluid into plasma.
Modelling the saturation of insulin effects on endogenous balance is thus a
very important feature of the model.
Figure 2.3: Maximal insulin effect as function of peripheral insulin concen-
tration (modified from [1])
Values in Figure 2.2 lie in the range (-0.154; 1). For the parameter
estimation it is more convenient to have a variable in the range (0; 1);
21
thus, the fraction of maximal endogenous balance is subjected to a linear
transformation into that range and interpreted as fraction of maximal insulin
effect, yielding the function shown in Figure 2.3.
Insulin resistance, or reduced insulin sensitivity is frequent in critical
illness [12], meaning that the ability for insulin-mediated glucose uptake is
constrained. The underlying mechanism is not entirely clarified, and the
relationship to clinical outcomes remains to be explained [76]. In the Glu-
cosafe model, insulin sensitivity is expressed as patient-specific parameter
s. Values for s are estimated from simulations of the model with the clin-
ical data of a patient, i.e. measured blood glucose concentrations, insulin
therapy and nutrition. s is reassessed when new data becomes available.
Thus, changes in values of s may reflect actual changes of a patient’s insulin
resistance state. s is approximately 1 for not insulin resistant subjects.
Figure 2.4: Effect of modelling insulin sensitivity s as scaling factor to either
peripheral insulin or to insulin effect (modified from [1])
Two different assumptions concerning the site of reduced insulin sensitiv-
ity in the model were analysed [1]. One option is to model insulin sensitivity
as a factor that scales the peripheral insulin concentration. This is schemat-
ically shown as arrow labelled spre in Figure 2.1, before the non-linearity.
A physiological interpretation for this option could be the impairment of
insulin delivery to skeletal muscle interstitium [77; 78], or a modification in
the dynamics of the binding and unbinding of insulin to its receptor. Figure
2.4 shows that scaling of the peripheral insulin concentration shifts the con-
centration at which half insulin effect is reached to the right. Alternatively,
the insulin sensitivity can be modelled as a scaling factor of fractional in-
sulin effect, after the non-linearity. This option is schematically shown as
arrow labelled spost in Figure 2.1. A physiological interpretation of this op-
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tion could be the down-regulation of the number of insulin receptors or a
modification in the intracellular insulin signalling pathway [79; 80]. Figure
2.4 shows that modelling this option preserves the shape of the non-linearity
function. A comparison of the two alternative approaches using retrospec-
tive data from 10 critically ill patients [1] favoured the second option. Thus,
the insulin sensitivity parameter is used as a scaling factor to the fraction
of maximum insulin effect i, yielding the (reduced) fractional insulin effect
a, as schematically shown in Figure 2.1.
The right part of Figure 2.1 shows the total glucose balance, which is
the sum of the endogenous glucose balance and the glucose appearance from
enteral and parenteral nutrition. The rate of parenteral glucose uptake p is
calculated directly from the infusion rate and glucose concentration of intra-
venous nutrition. The calculation of the rate of intestinal glucose absorption
involves two steps. In the first step, the absorption rate e is calculated from
the amount of carbohydrates N in the combined stomach and intestinal
reservoirs [74]. The second step involves the modelling of a slower gastric
emptying rate, like it is often found in enterally fed, critically ill patients
[81]. Impaired gastric emptying has been associated with a slower absorp-
tion of nutrients [82]. Thus, the absorption rate e is scaled to a reduced
value, as illustrated in Figure 2.5, with a scaling factor m that has been
estimated for a mixed critical care population [1] .
Figure 2.5: Intestinal glucose absorption rate e as function of the carbohy-
drate amount N . To model a slowed glucose absorption rate, e is scaled by
m (from [1])
Finally, the endogenous glucose balance is calculated using the trans-
porter model by Arleth et al. [74]. The endogenous glucose balance is
described by four compartments, two representing the insulin-independent
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glucose uptake and two representing the insulin-dependent glucose uptake.
The hepatic balance H and the GLUT4-mediated peripheral glucose up-
take PGLUT 4 are functions of the blood glucose concentration G and of the
fractional insulin effect a. The insulin-independent peripheral glucose up-
take PGLUT 1+3 represents the transport mediated by GLUT1 and GLUT3
transporters and is non-linearly dependent on the blood glucose. The renal
clearance R depends on the blood glucose and the glomerular filtration rate.
Figure 2.6 shows the resulting endogenous glucose balance E as a function
of blood glucose concentration and fractional insulin effect.
Figure 2.6: Endogenous glucose balance E as function of blood glucose G
and insulin effect a (from [1])
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Chapter 3
Parameter Identification
Method
This chapter shortly presents different parameter identification methods of
insulin sensitivity, and the results that were obtained from a comparison of
the methods. The content is based on publication III.
As shown in Chapter 2, the Glucosafe model has the patient-specific
parameter s, whose value is estimated based on treatment data and blood
glucose measurements. Thus, the estimated value of s varies over time and
may reflect changing insulin resistance states of a patient. Values for s that
are approximately 1 indicate a normal insulin response, whereas values that
are lower than 1 indicate insulin resistance.
The course of the ’future’ blood glucose is predicted based on the ’cur-
rent’ insulin sensitivity, assuming that deviations of insulin sensitivity from
its current value will be small over the near future. Naturally, as the predic-
tion time horizon increases, it becomes more likely that the future insulin
sensitivity differs from its assumed ’current’ value. From this, two conclu-
sions can be drawn. First, predictions of blood glucose in the nearer future
are more often more accurate than predictions with longer time horizon.
This relationship can be described as function of mean prediction error over
prediction time. Second, identification methods whose estimates of ’cur-
rent’ insulin sensitivity are on average more accurate than the estimates of
other methods, should lead to a reduction of mean prediction error. Thus,
a method comparison can be based on comparing mean prediction errors
over prediction time, assuming that the method with smallest mean predic-
tion error is the one whose estimates of insulin sensitivity are closest to the
insulin resistance state of a patient.
Based on these assumptions, blood glucose predictions by the Glucosafe
model were studied using retrospective clinical data from ten hyperglycemic
critically ill trauma and neurosurgical patients with five different identifica-
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tion methods of insulin sensitivity [3]. Compared were three least squares
approaches, an integral based method [83] and a Bayesian-least squares ap-
proach. The evaluation was based on a comparison of root mean square of
logarithmic prediction error for predictions with different time length, from
short (1–2 hours) to longer (9–10 hours) time horizons.
Figure 3.1: Root mean square (RMS) of log prediction error for five identi-
fication methods and varying prediction time lengths (modified from [3])
Figure 3.1 shows that the Bayesian least squares approach resulted in
the smallest root mean square of logarithmic prediction error over all time
intervals. This method also gave fewer and smaller outlying errors than the
other methods [3]. A patient case is shown in Figure 3.2 as a representative
example of the method comparison, that highlights the differences between
these methods. Each panel of Figure 3.2 represents one method. The meth-
ods differed with respect to the criteria by which measurements in the past
(up to 12 hours back) were included in the fit of the model-simulated blood
glucose, and thus, in the estimation of s. Green dots in the panels represent
measurements included for fitting, grey dots are excluded measurements.
Red dots are measurements that lie in the predicted future of the patient.
On average, the Bayesian-least squares approach yielded smaller predic-
tion errors than the other four methods. The Bayesian method is thus an
effective identification method for the parameter s with this model. This
result is preliminary; more patient cases will be necessary to verify this
result.
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Figure 3.2: Case comparison of five parameter identification methods.
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Chapter 4
Model Comparison
This chapter summarizes retrospective studies of the model, including a
comparison to other relevant models of glucose metabolism. The content is
based on publications IV and V.
Three-dimensional surfaces of plasma insulin, plasma glucose and re-
sulting rate of change in endogenous glucose balance were developed for a
quantitative comparison of four metabolic models [4]. The four models were
the Glucosafe model (named ’Receptor model’ or ’RM’ in this publication),
the minimal model (’MM’) [61] and two variants of a non-linear glycaemic
control model (’ND1’ and ’ND2’) [84], which has been studied retrospec-
tively and in in the evaluation of the SPRINT protocol [37].
Each surface was the result of a model fit to a set of 77 glycemic clamp
data points from hyperglycemic and normoglycaemic individuals with nor-
mal insulin sensitivity [74]. A grid search was used over physiological ranges
of important model variables to fit the data to minimum error metrics, look-
ing for a best error fit. The root mean square error and the frequency of
error near zero were the error metrics used and the minimum error set of
model variables was the same over both error metrics in each case. Note,
that no fitting of model variables was needed in this study for the Glucosafe
model whose endogenous glucose balance was already identified for the same
77 clamp data points [74]. Differences due to different saturation dynamics
along the glucose and insulin axes can be clearly distinguished from the sur-
face plots in Figure 4.1. The plots show that the Glucosafe model and the
ND2 model very similarly account for saturation effects on glucose balance
for high insulin and blood glucose concentrations, whereas both the minimal
model and the ND1 model surface plots show steady increases of endogenous
glucose balance.
In a second step, the model variables were left constant at the values
identified with the first data set, and only insulin sensitivity was allowed to
vary as a single parameter. In this setting it was assessed how well each
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Figure 4.1: Glucose-insulin pharmaco-dynamic surfaces of four metabolic
models, fitted to glycemic clamp data. A: Glucosafe model; B: Minimal
Model; C: ND1 (non-linear glycemic control model variant 1); D: ND2 (non-
linear glycemic control model variant 2) (from [4])
surface could fit another set of data. This second data set consisted of 146
glycemic clamps from a before-after intervention study of 73 normoglycemic
individuals with relatively lower insulin sensitivity [85]. Assuming that the
first and the second data were mainly set apart by a general reduction in
insulin sensitivity in the second data set, it was hypothesized that the second
set of data should be reasonably, although not optimally, fitted by reducing
insulin sensitivity alone.
Results for both data sets and different error metrics showed similar re-
sults for the Glucosafe model, ND1 and ND2, though a trend could be seen
for the Glucosafe model towards smaller error outliers compared to ND1 and
ND2. All three models showed the expected reduction in insulin sensitivity
with the fitting of the second data set. In contrast, the minimal model did
not accurately predict the change in cohort insulin sensitivity. Particularly
it was shown that the minimal model could fit only euglycemic regimens
tolerably well, while the same constants did not capture data from the hy-
perglycemic regime. This finding emphasizes the importance of modelling
insulin saturation dynamics as much as it highlights the minimal model’s
underperformance in states of hyperglycemic, insulin-resistant patients.
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The prediction accuracy of the Glucosafe model and the ND1 model [84]
was also compared in a retrospective study of 11 hyperglycemic patients
from two ICUs [5]. The two cohorts were made up by six patients from a
data pool of cross-sectional patients (’NZ’ group) and by five patients from
a neuro- and trauma ICU (’DK’ group). The groups differed in admission
diagnoses and in glycemic control methods. In the DK group, blood gas
analyzers were used for arterial blood analysis, and hyperglycemic patients
received continuous insulin infusions. In the NZ group, arterial blood was
sampled using bedside point-of-care glucose meters, and insulin was given
in the form of intravenous bolus injections. Due to those differences, the
glycemic prediction accuracy was compared for each cohort separately.
Figure 4.2: Root mean square (RMS) of log prediction error comparison of
two cohorts and different prediction time lengths (modified from [5])
Prediction errors were similar for the two models, as seen in Figure 4.2.
Both models predicted more accurately the blood glucose of patients from
the DK group. Measures of median and interquartile ranges of blood glu-
cose in these patients indicated better glycemic control and less fluctuation
in that particular patient group which may explain this outcome. The maxi-
mum difference in root mean square of prediction error did not exceed 4−5%
in both cohorts. Outlying prediction errors were dominated by type 1 dia-
betic patients. Both models had a tendency to underestimate large glycemic
changes.
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Chapter 5
Pilot Evaluation of Glucosafe
This chapter explains the design of the decision support system and sum-
marizes the results obtained from using the system in a clinical pilot trial.
The content is based on publications VI.
The Glucosafe model was implemented in a new decision support system
and tested in a prospective clinical trial [6]. Primary purpose of the study
was to demonstrate the system’s initial safety for tight glycemic control,
particularly with regard to the prevention of an increase of hypoglycemic
episodes that has been reported with other tight glycemic control stud-
ies [43]. The system was primarily used by the nurses of the ICU. The
main system components were the model, an advice generator, an interac-
tive graphical user interface and a database. Figure 5.1 schematically shows
the main components and the main sequence of communication flows during
operation of the system.
Figure 5.1: Main components and communication flows of the decision sup-
port system. Flows are represented as arrows. Communication loops during
advice generation (marked by ∗)
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1. The user enters a request over the graphical user interface. Possible
requests include:
(a) Enter clinical data for getting therapeutic advice. Clinical
data comprise the time and rate of enterally/parenterally admin-
istered nutrition, time and rate of propofol and insulin infusions,
time and amount of insulin boluses and time and values of blood
glucose concentrations. This function is invoked when new data
is available and triggers the generation of a new advice.
(b) Enter historic treatment or update the patient file. This
function is invoked to record the historic blood glucose measure-
ments and course of treatment for the patient (without triggering
advice generation). It is also invoked when a patient becomes
newly registered with the system, or when the patient journal is
updated (health evaluation scores, temperature, acquired infec-
tions, etc.).
(c) Accept/Reject/Modify advice. This function may be in-
voked after advice generation to accept, reject or modify the
therapeutic advice of the system.
2. Data and user request are stored in the database.
3. Data relevant to the user request are retrieved from the database.
The patient’s insulin sensitivity is identified using the Bayesian-least
squares fitting method [3]. The 3-hour blood glucose outcome of the
current treatment is predicted.
4. Suggest an intervention for parenteral and enteral nutrition, and in-
sulin infusion and/or bolus.
5. Predict the 3-hour blood glucose outcome of the suggested interven-
tion, compare to previously saved outcome and save the alternative
with the better outcome. Loop back to step 4, until the global opti-
mum has been found.
6. Communicate results of step 3 or final results of step 5 to the graphical
user interface. Calculate the infusion pump rates of parenteral/enteral
nutrition.
7. Display simulated and predicted blood glucose outcome to user. Show
updated insulin sensitivity index. List current and historic insulin
therapy and nutrition. Display advice (if applicable). Show schedule
for next blood glucose measurement. Prepare for new user request.
The system was installed as a stand-alone application on a portable
tablet PC with touch-sensitive screen. The interactive graphical user inter-
face used during the pilot study is shown in Figure 5.2. The nurses were
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instructed how to use the system in advance of the pilot study. During pilot
testing, the nurses were encouraged to operate the system under supervision
of one of the study investigators.
Figure 5.2: Graphical user interface of Glucosafe during the pilot trial of
the system. Labels are translated to English (from [6])
Four penalty scoring functions were developed and used for generating
the model-based advice. These functions assigned a penalty score to each
possible therapeutic regimen and its predicted blood glucose outcome. A
penalty score thus rated the undesirability of a particular choice or outcome
relative to the ’most desirable’ choice or outcome. Penalty scores rated (1)
the predicted 3-hour blood glucose concentration, compared to the target
range of 4.4 − 7.75 mmol/L, (2) use of insulin, compared to no insulin ther-
apy (and thus no hypoglycemic risk), (3) total caloric intake, as compared
to a feeding rate corresponding to the patient’s energy needs, and (4) use
of parenteral nutrition, compared to using the enteral feeding route. The
system advice resulted from the minimization of the sum of the penalty
scores, over the total search space of regimens and predicted blood glucose
outcomes.
10 hyperglycemic patients (median APACHE II: 12.5; interquartile range
7.5-16.3) from a neuro- and trauma intensive care unit at Aalborg hospital
were included for pilot testing of the system. Each patient was treated
according to Glucosafe advice for 12-14 hours. Outcomes and interven-
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tion during Glucosafe control were compared to the 24-hour intervals be-
fore and after using Glucosafe (’off-on-off’ study design). It was hypoth-
esized that glycemic control would improve during Glucosafe usage com-
pared to pre-intervention, and that glycemic control would worsen during
post-intervention.
No mild (< 3.5 mmol/L) or severe (< 2.2 mmol/L) hypoglycemia was
observed during the trial. The mean log-normal blood glucose during Glu-
cosafe intervention (7.0 ± 1.1 mmol/L) was significantly lower compared to
pre-intervention levels (8.6 ± 2.4 mmol/L; P < 0.01) and post-intervention
levels (7.4 ± 1.5 mmol/L; P=0.03). Measurements of all three intervals are
shown in the histogram in Figure 5.3. The lowest blood glucose measured
during the intervention was 4.8 mmol/L. The mean time to reach target
blood glucose range (4.4-6.1 mmol/L) was 5h. After exclusion of the ini-
tial 5h, mean log-normal blood glucose was 6.7 ± 1.2 mmol/L, and 40% of
the measurements were in the 4.4-6.1 mmol/L range and 84% of the mea-
surements were in the 4.4-7.75 mmol/L range. These results showed that
Glucosafe improved the glycemic control in this patient cohort, and the
system’s initial safety from hypoglycemia was demonstrated.
Figure 5.3: Blood glucose distributions during the Glucosafe study.
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Chapter 6
Integration of Glucosafe
This chapter outlines how Glucosafe can be incorporated into the routine
glycemic management of ICU patients. Part of the content is based on
publication VII.
Integration of a new system into an established working routine raises
questions of compatibility and user-acceptability by its intended users. The
Glucosafe system has been designed to be used for glycemic control in in-
tensive care units, and its intended users are primarily nurses. The system
was implemented as stand-alone application for pilot testing. Installed on
a single portable unit, the program needed to be carried from bedside to
bedside. Data had to be entered manually and were saved on the local
harddisk, with no means provided for data recovery, or data transmission
to another unit or database. The scheduling of blood glucose measurements
was unflexible. Outside the setting of a clinical trial, this system would be
doomed to failure.
The installation of the Glucosafe program at the site of a centrally placed
blood gas analyzer would be a first simple apprach towards integration of
the system into clinical routine. Ideally, a new blood gas analysis would
trigger an automatic advice by Glucosafe. A printout of the advice can be
taken back by the nurse to the patient bedside to adjust the infusion pumps,
and the printout can be saved to the patient journal.
Figure 6.1 shows a similar, although more advanced setup. Blood gas
analysis triggers an advice by the system, which is subsequently sent to the
hospital information system. From here the advice is accessible by users
anywhere in the hospital, such as by a nurse viewing a terminal computer at
the patient bedside. However, the system still needs to be updated manually
with infusion pump settings and type of nutrition. These are additional work
steps for the nurse and a potential source of error.
Alternatively, Glucosafe could be installed as a patient bedside monitor-
ing system that receives the necessary information from the infusion pumps
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Figure 6.1: Central installation of Glucosafe with blood gas analyzer
over a cable network. This setup is schematically shown in Figure 6.2. Con-
tinuous polling of the settings of the infusion pumps eliminates the manual
entering of timepoints and infusion rate changes. Only blood glucose mea-
surements would have to be entered manually. However, in the case that
these values are centrally stored and can be electronically accessed, a full au-
tomatization of glycemic control with the Glucosafe system can be realized,
as shown in Figure 6.2.
Figure 6.2: Fully automatized glycemic control process with Glucosafe
The user-acceptability of the system can be improved through added
value by the system. Examples are monitoring functions, alarm functions,
or automatic calculations. In the setup of Figure 6.2, an integrated Glucosafe
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system may monitor the feeding rates and display updated information of
accumulated caloric intake to the nurse. Another important safety issue can
be solved by monitoring the insulin infusion pump. A feature can be built
into Glucosafe that raises an alarm, if the pump continues to run at a rate
for which Glucosafe predicts hypoglycemia. A continuously updated graph
over changes of patient insulin sensitivity can assist in the health diagnosis
of a patient.
Added value can also be provided by enabling the system to work with a
flexible schedule of blood glucose measurements [7]. The accuracy of predic-
tions is model-specific [7]. Based on the estimated model-prediction error, a
graph of the expected error range for blood glucose predictions can be dis-
played along a time axis, as schematically shown in Figure 6.3. This range of
error will have the shape of a funnel that widens with prediction time length
[7]. Intersections of the upper and lower funnel edges with the target range
define the next time point for measuring blood glucose. An alarm function
can alert the user, if the calculated time point passed without action.
Figure 6.3: Flexible scheduling of measurements based on model prediction
error. Solid line: predicted blood glucose course. Dotted line: 95% model
prediction error range. Dashed lines: target range. In order to prevent
hyperglycemia and hypoglycemia, the next measurement must be scheduled
in 1-1.5 hours (modified from [7]).
37
Chapter 7
Discussion
This thesis summarizes the design, implementation and clinical pilot study
of a multi-compartment model of insulin-glucose metabolism to be used for
glucose control in critically ill patients. Based on this model, the computer-
ized decision support system ’Glucosafe’ significantly improved the glucose
concentrations in ten hyperglycemic patients of a neuro- and trauma inten-
sive care unit. In particular, hypoglycemia was not observed during control
with Glucosafe. The hypothesis could therefore be proven. However, these
results are preliminary in the sense that they were achieved in this subset of
relatively homogeneous patients, and that the control time of each patient
did not extend 14 hours. The clinical relevance and usefulness of the model
in a highly heterogeneous population of ’critically ill’ patients thus needs
careful evaluation.
The Glucosafe model presented in this thesis is a physiologically based
pharmacokinetic multi-compartment model for predicting the absorption,
distribution and metabolism of insulin and glucose in humans. The Glu-
cosafe compartments represent organs and tissue spaces and are parametrized
with volumes, transport rates and diffusion rates. This modelling method
has several strengths: (1) Parameter values can be estimated based on a
priori available information from various sources (from in vitro or in vivo
experiments, etc.). (2) The model gives also access to internal body con-
centrations of chemicals or their metabolites, and in particular at the site
of their effects. (3) Finally, the physiologically based modelling approach
leaves room for extrapolations. An example of a parametric extrapolation
from healthy subjects to critically ill subjects in the Glucosafe model is the
scaling of the rate of intestinal glucose absorption to simulate an impair-
ment of gastric absorption function. A number of parametric extrapolation
functions have been built into the computerized Glucosafe system. They
allow adjustments of the model to treat subjects of different gender, age,
height, weight, diabetic state, or gastric impairment. Glucosafe’s decision
support is also parametrized; the advice module takes an estimate of the
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patient’s required energy as input to generate a patient-specific recommen-
dation. ’Nonparametric’ extrapolations (requiring a change in the model
structure) have the potential to make the model usable for a broader range
of patients. For example, extending the model with an additional ’stom-
ach’ compartment could be a necessary element for the use of the system in
patients who eat meals. However, extensions to the model increase its com-
plexity, and the net benefit of adding structural information to the model
should therefore be carefully quantified.
In critical illness, glycogenolysis and hepatic EGP1 vary over time: the
stores of glycogen are rapidly exhausted after injury, while EGP is mainly
dependent on the amount of neoglucogenic substrates provided, and of the
the hepatic function. A physiological adaptation of the model, using time
from injury as a variable, should be analyzed. The data material from the
pilot study is not suitable for such an analysis, as the data only capture the
first days of patients in intensive care. Other events, such as febrile days or
the administration of exogenous catecholamines and steroids, are associated
with decreased insulin sensitivity. The capability of the model to capture
these kinds of events by reduced estimates of insulin sensitivity should also
be studied specifically.
Glucosafe’s predictive accuracy has been retrospectively evaluated using
data from observational studies. Parts of the data material have also been
used for training the model. Since the predictive performance was maxi-
mized on the training data set, the model may have been overfit. A model
which has been overfit will generally have poor predictive performance, as
it can exaggerate minor fluctuations in the data. This possibility must be
ruled out, by statistic tests (Chi-Square) and by testing predictive perfor-
mance on unseen data. If overfitting has occurred, the training data set
must be enlarged and supplemented with heterogeneous patient data, and
the maximization of predictive performance must be repeated.
The pilot testing of the system included 10 hyperglycemic patients from
a single-centre neuro- and trauma intensive care unit. Blood glucose levels
were significantly reduced; after a mean of 5 h to reach the target range
(4.4-6.1 mmol/l), the mean log-normal blood glucose concentration had been
reduced to 6.7 ± 1.2 mmol/l and 40% of the measurements were in the 4.4-
6.1 mmol/l range and 84% were in the 4.4-7.75 mmol/l range. These are
initial results that compare well to results achieved by other computerized
decision support systems for blood glucose control in intensive care units
[67]. In a prospective 3-centre study of GRIP [86] in surgical, neurosurgical
and cardiothoracic patients, the time to capture the target range (4-7.5
mmol/l) was 5.6 h, and 89% of measurements were within this range for the
remaining time [67]. The achieved glucose variability was 1.2 mmol/l and
was also similar to that achieved in the Glucosafe pilot study.
1endogenous glucose production
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Finally, the Glucosafe model and system needs to be tested in clinical tri-
als to address a wider range of validation considerations, including those of
usability, acceptability, reliability, etc. The clinical trials should be designed
to assess the quality of glucose control with Glucosafe as compared to stan-
dard care and/or other clinical decision support systems using predefined
glucose indicators for the comparison [87].
In conclusion: Preliminary results indicate significantly improved glycemic
control with the model-based Glucosafe decision support system. Further
studies are necessary to confirm these initial findings and to clarify the need
for model improvements. Various solutions for system integration into rou-
tine management of critically ill patients have been outlined.
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Chapter 8
Dansk Resumé
Hyperglykæmi observeres hyppigt hos patienter på intensivafdelinger og er
blevet associeret med forringede behandlingsresultater. Stram glykæmisk
kontrol har vist en reduktion i mortalitet og morbiditet in nogle grupper
af kritisk syge patienter, dog er hypoglykæmi den primære bivirkning af
stram glykæmisk kontrol. Den øgede risiko for hypoglykæmi samt den tid
og indsats der er forbundet med intensiv insulin protokoller har startet en
debat omkring fordele og ulemper ved stram glykæmisk kontrol på intensiv
afdelinger.
Denne afhandling opsummerer arbejdet på design, implementering og et
klinisk pilotforsøg af et modelbaseret computerprogram til beslutningsstøtte
i glykæmisk kontrol hos intensiv patienter. Dette system, kaldet ’Glu-
cosafe’, giver anbefalinger angående insulinbehandling og ernæringsmæssig
indtag til intensiv patienter med hyperglykæmi, til brug for det kliniske
personale. Kernen af systemet er en kompartment model af insulin-glukose
metabolismen. En plasma kompartment og en perifer kompartment i mod-
ellen beskriver farmakokinetiken tilknyttet insulin fra intravenøse infusioner
eller boluser og fra den endogene insulinproduktion. Den farmakodynamiske
effekt af insulin er beskrevet af det funktionelle forhold mellem insulin i
det ekstracellulære rum og effekten på glukose optag i insulin-sensitivt væv.
Modellen redegør for mætningen af insulineffekten ved høje koncentrationer,
hvilket forhindrer behandlingsmæssige anbefalinger af for høje insulin doser,
der kan øge risikoen for hypoglykæmi. Glukose metabolismen håndteres i
modellen således at glukose absorptionen i mave-tarm systemet og den in-
travenøse glukoseinfusion er modelleret som inputs til blodglukose kompart-
menten. Den endogene glukosebalance er beskrevet af en transportermodel
af den hepatiske balance, nyrernes glukose optagelse og glukose optagelse på
de perifere sites. Insulinfølsomheden er estimeret som en patient parame-
ter, der er en indeks for patientens glykæmiske status. I modellen medfører
formindsket insulinfølsomhed en reduceret maksimal opnåelig insulin effekt.
Som parameter estimeringsmetode foreslås en bayesiansk fremgangsmåde
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på baggrund af en sammenligning af forskellige identifikationsmetoder. Til
den rådgivende del af systemet blev der udviklet fire straffefunktioner, som
straffer brug af for høje insulindoser, under- eller overernæring, brug af en
parenteral ernæringsform og forudsagt hyper- eller hypoglykæmi som be-
handlingsresultat. Anbefalingerne er baseret på en minimering af summen
af straffepoint, men systemet giver også mulighed for manuelt at ændre
ernæringsanbefalingen.
Nøjagtigheden i Glucosafe’s forudsigelser blev testet i et retrospektivt
studie af ti hyperglykæmiske kritisk syge neuro- og traumepatienter. For
hver patient var medianen af den absolutte procentfejl mindre end 25%
for forudsigelsestider mindre eller lig med 270 min. Til prospektiv test af
systemet blev der udviklet en interaktivt grafisk brugergrænseflade. Det
prospektive pilotstudie af Glucosafe systemet blev udført på neuro- og traume
intensiv afdelingen på Aalborg sygehus. Studiet viste en forbedret glykæmisk
kontrol med anvendelse af Glucosafe, og der opstod ingen episoder med
hypoglykæmi under studiet. Afhandlingen afsluttes med nogle betragt-
ninger angående bruger acceptabilitet og systemintegration samt en skit-
sering af den kliniske arbejdsgang med Glucosafe som et praktisk værktøj
til glykæmisk kontrol på intensiv afdelinger.
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